SRR5088894
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.500
- CHOLESTEROL_HOMEOSTASIS+0.200
- DNA_REPAIR+0.200
- E2F_TARGETS+0.200
- GLYCOLYSIS+0.200
- HEDGEHOG_SIGNALING+0.200
- MITOTIC_SPINDLE+0.200
- MYC_TARGETS_V1+0.200
- UNFOLDED_PROTEIN_RESPONSE+0.200
- G2M_CHECKPOINT+0.100
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.600
- INTERFERON_GAMMA_RESPONSE-0.600
- ALLOGRAFT_REJECTION-0.500
- INFLAMMATORY_RESPONSE-0.500
- KRAS_SIGNALING_UP-0.500
- COMPLEMENT-0.400
- IL6_JAK_STAT3_SIGNALING-0.400
- ANGIOGENESIS-0.300
- COAGULATION-0.300
- ESTROGEN_RESPONSE_LATE-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR5088895 | — | — | 0.959 |
| 2 | SRR6013533 | — | cohortSQ2 | 0.881 |
| 3 | 064ec215-7600-4e5d-be51-e757284f3e54 | — | — | 0.868 |
| 4 | SRR2780123 | — | — | 0.866 |
| 5 | 20120209.TNBC | — | E | 0.859 |
| 6 | dfc53815-0784-48c7-84aa-f23d087a13df | — | — | 0.858 |
| 7 | TCGA-J1-A4AH-01A-31R-A24H-07 | — | cohortSQ2 | 0.857 |
| 8 | sclc2008_S40.txt | — | cohortSC | 0.854 |
| 9 | 15d39440-6bb8-4ecb-add1-9ae8b007dc70 | — | — | 0.848 |
| 10 | MDT-AP-0574 | Med | Medulloblastoma | 0.847 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.500 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.200 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.200 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.200 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.100 | Inavolisib | — uncovered |
| HYPOXIA | 0.100 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.100 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.100 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.100 | Idelalisib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.100 | Remibrutinib | — uncovered |